Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Sutro Biopharma, Inc. (STRO) reported a Q4 loss of $0.89 per share, slightly worse than the expected loss of $0.86. However, the company exceeded revenue estimates.
March 14, 2025 | 12:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sutro Biopharma reported a Q4 loss of $0.89 per share, missing the consensus estimate of a $0.86 loss. Despite this, the company exceeded revenue expectations.
The slight miss on EPS could be seen negatively, but the beat on revenue may offset this, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100